Literature DB >> 29752601

Borrmann Type 1 Cancer is Associated with a High Recurrence Rate in Locally Advanced Gastric Cancer.

Ji Hyun Kim1, Han Hong Lee2, Ho Seok Seo1, Yoon Ju Jung1, Cho Hyun Park1.   

Abstract

BACKGROUND: This study aimed to investigate the clinicopathologic characteristics and outcomes of Borrmann type 1 gastric cancer and evaluate its clinical significance in advanced gastric cancer compared with Borrmann types 2 and 3 cancer.
METHODS: Between January 1989 and December 2013, 1949 patients with advanced gastric cancer who underwent curative gastrectomy at our institution were enrolled in the study.
RESULTS: Of the 1949 patients, 59 (3%) exhibited Borrmann type 1 cancer, characterized by a large size, rare serosal invasion, lower lymph node involvement, location in the upper third of the stomach, intestinal type, and differentiated histology. The recurrence rate was higher for Borrmann type 1 than for Borrmann types 2 and 3 cancer. In addition, more than half of the Borrmann type 1 recurrences showed a hematogenous pattern. However, overall survival did not differ significantly among the three cancer types. In the multivariate analysis, Borrmann type 1 cancer, with tumor depth, node metastasis, and vascular invasion, was an independent risk factor associated with recurrence. Particularly, Borrmann type 1 cancer showed a worse prognosis in both overall survival and recurrence-free survival than the other Borrmann types in the upper third of the stomach.
CONCLUSIONS: Borrmann type 1 gastric cancer is associated with a higher recurrence rate than Borrmann types 2 and 3, but not with a difference in the overall survival rate.

Entities:  

Mesh:

Year:  2018        PMID: 29752601     DOI: 10.1245/s10434-018-6509-3

Source DB:  PubMed          Journal:  Ann Surg Oncol        ISSN: 1068-9265            Impact factor:   5.344


  5 in total

1.  Combined Surgery and Extensive Intraoperative Peritoneal Lavage vs Surgery Alone for Treatment of Locally Advanced Gastric Cancer: The SEIPLUS Randomized Clinical Trial.

Authors:  Jing Guo; Aman Xu; Xiaowei Sun; Xuhui Zhao; Yabin Xia; Huamin Rao; Yaming Zhang; Rupeng Zhang; Li Chen; Tao Zhang; Gang Li; Hongtao Xu; Dazhi Xu
Journal:  JAMA Surg       Date:  2019-07-01       Impact factor: 14.766

2.  LACTB and LC3 could serve as potential biomarkers of gastric cancer to neoadjuvant chemotherapy with oxaliplatin plus S-1.

Authors:  Fang Yang; Zhiqiang Yan; Wei Nie; Zeying Liu; Xingzhen Cheng; Wei Wang; Chunyan Shao; Gui Fu; Yanni Yu
Journal:  Oncol Lett       Date:  2021-04-13       Impact factor: 2.967

3.  The protocol of a prospective, multicenter, randomized, controlled phase III study evaluating different cycles of oxaliplatin combined with S-1 (SOX) as neoadjuvant chemotherapy for patients with locally advanced gastric cancer: RESONANCE-II trial.

Authors:  Xinxin Wang; Shuo Li; Yihong Sun; Kai Li; Xian Shen; Yingwei Xue; Pin Liang; Guoli Li; Luchuan Chen; Qun Zhao; Guoxin Li; Weihua Fu; Han Liang; Hairong Xin; Jian Suo; Xuedong Fang; Zhichao Zheng; Zekuan Xu; Huanqiu Chen; Yanbing Zhou; Yulong He; Hua Huang; Linghua Zhu; Kun Yang; Jiafu Ji; Yingjiang Ye; Zhongtao Zhang; Fei Li; Xin Wang; Yantao Tian; Sungsoo Park; Lin Chen
Journal:  BMC Cancer       Date:  2021-01-05       Impact factor: 4.430

4.  Three-year outcomes of the randomized phase III SEIPLUS trial of extensive intraoperative peritoneal lavage for locally advanced gastric cancer.

Authors:  Jing Guo; Aman Xu; Xiaowei Sun; Xuhui Zhao; Yabin Xia; Huamin Rao; Yaming Zhang; Rupeng Zhang; Li Chen; Tao Zhang; Gang Li; Hongtao Xu; Dazhi Xu
Journal:  Nat Commun       Date:  2021-11-15       Impact factor: 14.919

5.  Health-Related Quality of Life in Patients With Locally Advanced Gastric Cancer Undergoing Perioperative or Postoperative Adjuvant S-1 Plus Oxaliplatin With D2 Gastrectomy: A Propensity Score-Matched Cohort Study.

Authors:  Jianhong Yu; Zaozao Wang; Zhexuan Li; Ying Liu; Yingcong Fan; Jiabo Di; Ming Cui; Jiadi Xing; Chenghai Zhang; Hong Yang; Zhendan Yao; Nan Zhang; Lei Chen; Maoxing Liu; Kai Xu; Fei Tan; Pin Gao; Xiangqian Su
Journal:  Front Oncol       Date:  2022-04-04       Impact factor: 5.738

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.